Presence of -Lactamase-Producing Enterobacterales and Salmonella
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Proteus Vulgaris
48 Monte Carlo Crescent Kyalami Business Park Kyalami, Johannesburg, 1684, RSA Tel: +27 (0)11 463 3260 Fax: + 27 (0)86 557 2232 Email: [email protected] www.thistle.co.za Please read this section first The HPCSA and the Med Tech Society have confirmed that this clinical case study, plus your routine review of your EQA reports from Thistle QA, should be documented as a “Journal Club” activity. This means that you must record those attending for CEU purposes. Thistle will not issue a certificate to cover these activities, nor send out “correct” answers to the CEU questions at the end of this case study. The Thistle QA CEU No is: MT- 16/009 Each attendee should claim THREE CEU points for completing this Quality Control Journal Club exercise, and retain a copy of the relevant Thistle QA Participation Certificate as proof of registration on a Thistle QA EQA. MICROBIOLOGY LEGEND CYCLE 41 ORGANISM 3 Proteus Vulgaris Proteus Vulgaris is a rod shaped Gram-Negative chemoheterotrophic bacterium. The size of the individual cells varies from 0.4 to 0.6 micrometers by 1.2 to 2.5 micrometers. P. vulgaris possesses peritrichous flagella, making it actively motile. It inhabits the soil, polluted water, raw meat, gastrointestinal tracts of animals and dust. In humans, Proteus species most frequently cause urinary tract infections, but can also produce severe abscesses and is widely associated with nosocomial infections. Isolation of Organism With basic microbiological technique, samples believed to contain P. vulgaris are first incubated on nutrient agar to form colonies. To test the Gram-Negative and oxidase-negative characteristics of Enterobacteriaceae, Gram stains and oxidase tests are performed. -
Isbn 978-625-409-353-1
ISBN 978-625-409-353-1 INTERNATIONAL CONGRESS ON BIOLOGICAL AND HEALTH SCIENCES PROCEEDİNGS BOOK This work is subject to copyright and all rights reserved, whether the whole or part of the material is concerned. The right to publish this book belongs to International Congress on Biological and Health Sciences-2021. No part of this publication may be translated, reproduced, stored in a computerized system, or transmitted in any form or by any means, including, but not limited to electronic, mechanical, photocopying, recording without written permission from the publisher. This Proceedings Book has been published as an electronic publication (e-book). The publisher is not responsible for possible damages, which may be a result of content derived from this electronic publication All authors are responsible for the contents of their abstracts. https://www.biohealthcongress.com/ ([email protected]) Editor Ulaş ACARÖZ Published: 28/03/2021 ISBN: Editor's Note The first ‘International Congress on Biological and Health Sciences’ was organized online and free of charge. We are very happy and proud that various health science-related fields attended the congress. By this event, the distinguished and respected scientists came together to exchange ideas, develop and implement new researches and joint projects. There were 15 invited speakers from 10 different countries and also approximately 400 submissions were accepted from more than 20 countries. We would like to thank all participants and supporters. Hope to see you at our next congress. -
Transposon Mutagenesis in Proteus Mirabilist
JOURNAL OF BACTERIOLOGY, OCt. 1991, p. 6289-6293 Vol. 173, No. 19 0021-9193/91/196289-05$02.00/0 Copyright © 1991, American Society for Microbiology NOTES Transposon Mutagenesis in Proteus mirabilist ROBERT BELAS,1,2* DEBORAH ERSKINE,1 ANID DAVID FLAHERTY1 Center of Marine Biotechnology, The University of Maryland, 600 East Lombard Street, Baltimore, Maryland 21202,1* and Department ofBiological Sciences, University of Maryland Baltimore County, Baltimore, Maryland 212282 Received 21 June 1991/Accepted 24 July 1991 A technique of transposon mutagenesis involving the use of TnS on a suicide plasmid was developed for Proteus mirabilis. Analysis of the resulting exconjugants indicated that TnS transposed in P. mirabilis at a frequency of ca. 4.5 x 10-6 per recipient cell. The resulting mutants were stable and retained the transposon-encoded antibiotic resistance when incubated for several generations under nonselective conditions. The frequency of auxotrophic mutants in the population, as well as DNA-DNA hybridization to transposon sequences, confirmed that the insertion of the transposon was random and the Proteus chromosome did not contain significant insertional hot spots of transposition. Approximately 35% of the mutants analyzed possessed plasmid-acquired ampicillin resistance, although no extrachromosomal plasmid DNA was found. In these mutants, insertion of the Tn5 element and a part or all of the plasmid had occurred. Application of this technique to the study of swarmer cell differentiation in P. mirabilis is discussed. Proteus mirabilis is a motile gram-negative bacterium with Media and growth conditions. Escherichia coli and P. the unique ability to move over agar surfaces by a locomo- mirabilis strains were grown in L broth (10 g of tryptone, 5 tive process referred to as swarming motility (12). -
Bacterial Dissimilation of Citric Acid Carl Robert Brewer Iowa State College
Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1939 Bacterial dissimilation of citric acid Carl Robert Brewer Iowa State College Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Microbiology Commons Recommended Citation Brewer, Carl Robert, "Bacterial dissimilation of citric acid " (1939). Retrospective Theses and Dissertations. 13227. https://lib.dr.iastate.edu/rtd/13227 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Brol<en or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. -
Examining the Antimicrobial Activity of Cefepime-Taniborbactam
Examining the antimicrobial activity of cefepime-taniborbactam (formerly cefepime/VNRX-5133) against Burkholderia species isolated from cystic fibrosis patients in the United States Elise T. Zeiser1, Scott A. Becka1, John J. LiPuma2, David A. Six 3, Greg Moeck 3, and Krisztina M. Papp-Wallace1,4 1Veterans Affairs Northeast Ohio Healthcare System, Cleveland, OH; 2University of Michigan, Ann Arbor, MI; 3Venatorx 4 Pharmaceuticals, Inc., Malvern, PA; and Case Western Reserve University, Cleveland, OH Correspondence to: [email protected] Abstract Results Background: Burkholderia cepacia complex (Bcc), a group of >20 related species, and B. gladioli are 60 opportunistic human pathogens that cause chronic infections in people with cystic fibrosis (CF) or cefepime compromised immune systems. Ceftazidime and trimethoprim-sulfamethoxazole are first-line agents used to treat infections due to Burkholderia spp. However, these species have developed resistance to cefepime-taniborbactam many antibiotics, including first-line therapies. β-lactam resistance in Burkholderia species is largely 40 mediated by PenA-like chromosomal class A β-lactamases. A novel investigational β-lactam/β-lactamase inhibitor combination, cefepime-taniborbactam (formerly cefepime/VNRX-5133) demonstrates potent antimicrobial activity against gram-negative bacteria producing class A, B, C, and D β-lactamases. The activity of cefepime-taniborbactam was investigated against Bcc and B. gladioli; moreover, the biochemical activity of taniborbactam against the PenA1 carbapenemase was evaluated. 20 Methods: CLSI-based agar dilution antimicrobial susceptibility testing using cefepime and cefepime combined with taniborbactam at 4 mg/L was conducted against a curated panel of 150 Burkholderia species obtained from the Burkholderia cepacia Research Laboratory and Repository. Isolates were Number isolates of recovered from respiratory specimens from 150 different individuals with CF receiving care in 68 cities 0 throughout 36 states within the United States. -
E. Coli: Serotypes Other Than O157:H7 Prepared by Zuber Mulla, BA, MSPH DOH, Regional Epidemiologist
E. coli: Serotypes other than O157:H7 Prepared by Zuber Mulla, BA, MSPH DOH, Regional Epidemiologist Escherichia coli (E. coli) is the predominant nonpathogenic facultative flora of the human intestine [1]. However, several strains of E. coli have developed the ability to cause disease in humans. Strains of E. coli that cause gastroenteritis in humans can be grouped into six categories: enteroaggregative (EAEC), enterohemorrhagic (EHEC), enteroinvasive (EIEC), enteropathogenic (EPEC), enterotoxigenic (ETEC), and diffuse adherent (DAEC). Pathogenic E. coli are serotyped on the basis of their O (somatic), H (flagellar), and K (capsular) surface antigen profiles [1]. Each of the six categories listed above has a different pathogenesis and comprises a different set of O:H serotypes [2]. In Florida, gastrointestinal illness caused by E. coli is reportable in two categories: E. coli O157:H7 or E. coli, other. In 1997, 52 cases of E. coli O157:H7 and seven cases of E. coli, other (known serotype), were reported to the Florida Department of Health [3]. Enteroaggregative E. coli (EAEC) - EAEC has been associated with persistent diarrhea (>14 days), especially in developing countries [1]. The diarrhea is usually watery, secretory and not accompanied by fever or vomiting [1]. The incubation period has been estimated to be 20 to 48 hours [2]. Enterohemorrhagic E. coli (EHEC) - While the main EHEC serotype is E. coli O157:H7 (see July 24, 1998, issue of the “Epi Update”), other serotypes such as O111:H8 and O104:H21 are diarrheogenic in humans [2]. EHEC excrete potent toxins called verotoxins or Shiga toxins (so called because of their close resemblance to the Shiga toxin of Shigella dysenteriae 1This group of organisms is often referred to as Shiga toxin-producing E. -
Escherichia Coli
log bio y: O ro p c e i n M A l c Clinical Microbiology: Open a c c i e n s i l s Delmas et al., Clin Microbiol 2015, 4:2 C Access ISSN: 2327-5073 DOI:10.4172/2327-5073.1000195 Commentary Open Access Escherichia coli: The Good, the Bad and the Ugly Julien Delmas*, Guillaume Dalmasso and Richard Bonnet Microbes, Intestine, Inflammation and Host Susceptibility, INSERM U1071, INRA USC2018, Université Clermont Auvergne, Clermont-Ferrand, France *Corresponding author: Julien Delmas, Microbes, Intestine, Inflammation and Host Susceptibility, INSERM U1071, INRA USC2018, Université Clermont Auvergne, Clermont-Ferrand, France, Tel: +334731779; E-mail; [email protected] Received date: March 11, 2015, Accepted date: April 21, 2015, Published date: Aptil 28, 2015 Copyright: © 2015 Delmas J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract The species Escherichia coli comprises non-pathogenic commensal strains that form part of the normal flora of humans and virulent strains responsible for acute infections inside and outside the intestine. In addition to these pathotypes, various strains of E. coli are suspected of promoting the development or exacerbation of chronic diseases of the intestine such as Crohn’s disease and colorectal cancer. Description replicate within both intestinal epithelial cells and macrophages. These properties were used to define a new pathotype of E. coli designated Escherichia coli is a non-sporeforming, facultatively anaerobic adherent-invasive E. -
Table S4. Phylogenetic Distribution of Bacterial and Archaea Genomes in Groups A, B, C, D, and X
Table S4. Phylogenetic distribution of bacterial and archaea genomes in groups A, B, C, D, and X. Group A a: Total number of genomes in the taxon b: Number of group A genomes in the taxon c: Percentage of group A genomes in the taxon a b c cellular organisms 5007 2974 59.4 |__ Bacteria 4769 2935 61.5 | |__ Proteobacteria 1854 1570 84.7 | | |__ Gammaproteobacteria 711 631 88.7 | | | |__ Enterobacterales 112 97 86.6 | | | | |__ Enterobacteriaceae 41 32 78.0 | | | | | |__ unclassified Enterobacteriaceae 13 7 53.8 | | | | |__ Erwiniaceae 30 28 93.3 | | | | | |__ Erwinia 10 10 100.0 | | | | | |__ Buchnera 8 8 100.0 | | | | | | |__ Buchnera aphidicola 8 8 100.0 | | | | | |__ Pantoea 8 8 100.0 | | | | |__ Yersiniaceae 14 14 100.0 | | | | | |__ Serratia 8 8 100.0 | | | | |__ Morganellaceae 13 10 76.9 | | | | |__ Pectobacteriaceae 8 8 100.0 | | | |__ Alteromonadales 94 94 100.0 | | | | |__ Alteromonadaceae 34 34 100.0 | | | | | |__ Marinobacter 12 12 100.0 | | | | |__ Shewanellaceae 17 17 100.0 | | | | | |__ Shewanella 17 17 100.0 | | | | |__ Pseudoalteromonadaceae 16 16 100.0 | | | | | |__ Pseudoalteromonas 15 15 100.0 | | | | |__ Idiomarinaceae 9 9 100.0 | | | | | |__ Idiomarina 9 9 100.0 | | | | |__ Colwelliaceae 6 6 100.0 | | | |__ Pseudomonadales 81 81 100.0 | | | | |__ Moraxellaceae 41 41 100.0 | | | | | |__ Acinetobacter 25 25 100.0 | | | | | |__ Psychrobacter 8 8 100.0 | | | | | |__ Moraxella 6 6 100.0 | | | | |__ Pseudomonadaceae 40 40 100.0 | | | | | |__ Pseudomonas 38 38 100.0 | | | |__ Oceanospirillales 73 72 98.6 | | | | |__ Oceanospirillaceae -
Worldwide Links Between Proteus Mirabilis and Rheumatoid Arthritis
al of Arth rn ri u ti o s J Journal of Arthritis Wilson et al., J Arthritis 2015, 4:1 10.4172/2167-7921.1000142 ISSN: 2167-7921 DOI: Review Open access Worldwide Links between Proteus mirabilis and Rheumatoid Arthritis Clyde Wilson1*, Taha Rashid2 and Alan Ebringer2 1Department of Pathology, King Edward VII Memorial Hospital, Paget DV 07, Bermuda 2Analytical Sciences Group, King’s College London, Stamford Road, London SE1 9NN, UK *Corresponding author: Dr. Clyde Wilson, Department of Pathology, King Edward VII Memorial Hospital, Paget DV 07, Bermuda, USA, Tel: +1-4412391011; Fax: +1-4412392193; Email: [email protected] Rec date: November 26, 2014; Acc date: January 9, 2015; Pub date: January 15, 2015 Copyright: © 2015 Wilson C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Rheumatoid arthritis (RA) is a systemic and arthritic autoimmune disease affecting millions of people throughout the world. During the last 4 decades extensive data indicate that subclinical urinary tract infection by Proteus mirabilis has a role in the aetiopathogenesis of RA based on cross-reactivity or molecular mimicry between Proteus haemolysin and RA-associated HLA-DRB1 alleles as well as between Proteus urease and type XI collagen. Studies from 15 countries have shown that antibodies against Proteus microbes were elevated significantly in patients with active RA in comparison to healthy and non-RA disease controls. Proteus microbes could also be isolated more frequently in the urine of patients with RA than in controls. -
Shigella and Escherichia Coli at the Crossroads: Machiavellian Masqueraders Or Taxonomic Treachery?
J. Med. Microbiol. Ð Vol. 49 2000), 583±585 # 2000 The Pathological Society of Great Britain and Ireland ISSN 0022-2615 EDITORIAL Shigella and Escherichia coli at the crossroads: machiavellian masqueraders or taxonomic treachery? Shigellae cause an estimated 150 million cases and genera. One authority has even proposed that entero- 600 000 deaths annually, and can cause disease after haemorrhagic E. coli EHEC) such as E. coli O157:H7 ingestion of as few as 10 bacterial cells [1]. They are are essentially `Shigella in a cloak of E. coli antigens' spread by the faecal±oral route, with food, water, [7]. fomites, insects especially ¯ies) and direct person-to- person contact. S. dysenteriae causes brisk and deadly Shigella-like strains of E. coli that cause an invasive, epidemics, particularly in the developing world; S. dysenteric diarrhoeal illness were ®rst described in ¯exneri and S. sonnei account for the endemic form of 1971, over a decade before the appearance in 1982 of the disease, particularly in industrialised nations; S. the new EHEC strains that launched the current wave boydii is rarely encountered [1, 2]. of interest in the E. coli±Shigella connection [8]. Termed `enteroinvasive E. coli' EIEC), these strains, Shigellosis is a locally invasive colitis in which bacteria like shigellae, were able to invade and proliferate invade and proliferate within colonocytes and mucosal within intestinal epithelial cells, eventually causing cell macrophages, trigger apoptosis of macrophages and death [4, 8]. EIEC share with shigellae a c. 140-MDa spread through the mucosa from cell to cell [1]. plasmid pINV) that encodes several outer-membrane Cytokines produced by epithelial cells and macro- proteins involved in invasion of host cells [4, 8]. -
Citrobacter Koseri, Levinea Malonatica
INTERNATIONALJOURNAL OF SYSTEMATICBACTERIOLOGY, Jan. 1990, p. 107-108 Vol. 40, No. 1 0020-7713/90/010107-02$02.oo/o Copyright 0 1990, International Union of Microbiological Societies Correct Names of the Species Citrobacter koseri, Levinea malonatica , and Citrobacter diversus Request for an Opinion WILHELM FREDERIKSEN Department of Diagnostic Bacteriology and Antibiotics, Statens Seruminstitut, DK-2300 Copenhagen S,Denmark The single species carrying the three names Citrobacter koseri, Levinea malonatica, and Citrobacter diversus differs by at least eight characteristics from Citrobacter diversum as described by Werkman and Gillen in 1932. It is obviously not the same organism. Accordingly, the species should not carry the name proposed by Werkman and Gillen. I request that the name Citrobacter diversus be placed on the list of nomina rejicienda. Citrobacter koseri is the correct name. Levinea koseri is a correct combination when the genus Levinea is accepted. The epithet maZoonatica is a later synonym of the epithet koseri. In 1932 Werkman and Gillen (7) proposed a new genus, taxon C. diversum described by Werkman and Gillen in the Citrobacter, containing seven species. The description of following characteristics: motility, production of H,S, and Citrobacter diversum (sic) of Werkman and Gillen was based production of acid from inositol and raffinose. To this can be on two strains. These strains have not been kept available in added production of acid from glycogen, melizitose, starch, collections, and the name C. diversum did not come into and galactose, as Table 1 shows. general use. Ewing and Davis obviously accepted four deviations to In 1970 Frederiksen (4) described a new species which he lead to the statement about reactions “similar to those named Citrobacter koseri. -
Biomedical Applications of Bacteria-Derived Polymers
polymers Review Biomedical Applications of Bacteria-Derived Polymers Jonathan David Hinchliffe, Alakananda Parassini Madappura, Syed Mohammad Daniel Syed Mohamed and Ipsita Roy * Department of Materials Science and Engineering, Faculty of Engineering, University of Sheffield, Sheffield S1 3JD, UK; jhinchliffe3@sheffield.ac.uk (J.D.H.); [email protected] (A.P.M.); smdsyedmohamed1@sheffield.ac.uk (S.M.D.S.M.) * Correspondence: I.Roy@sheffield.ac.uk; Tel.: +44-11-4222-5962 Abstract: Plastics have found widespread use in the fields of cosmetic, engineering, and medical sciences due to their wide-ranging mechanical and physical properties, as well as suitability in biomedical applications. However, in the light of the environmental cost of further upscaling current methods of synthesizing many plastics, work has recently focused on the manufacture of these polymers using biological methods (often bacterial fermentation), which brings with them the advantages of both low temperature synthesis and a reduced reliance on potentially toxic and non-eco-friendly compounds. This can be seen as a boon in the biomaterials industry, where there is a need for highly bespoke, biocompatible, processable polymers with unique biological properties, for the regeneration and replacement of a large number of tissue types, following disease. However, barriers still remain to the mass-production of some of these polymers, necessitating new research. This review attempts a critical analysis of the contemporary literature concerning the use of a number of bacteria-derived polymers in the context of biomedical applications, including the biosynthetic Citation: Hinchliffe, J.D.; Parassini pathways and organisms involved, as well as the challenges surrounding their mass production.